PRQRHealthcare · BiotechnologyThe 9 Wall Street analysts covering ProQR Therapeutics NV hold a median 12-month price target of $8 — +467.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 3 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores ProQR Therapeutics NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (70): Sales and profits are climbing, and climbing faster than before.
Accruals (32): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PRQR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +467.4% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Chardan Capital | Maintains | Buy | $3.00 |
| 1 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $12 → $8.00 |
| 20 Aug 2026 | B of A Securities | Initiates | Buy | — |
| 20 Aug 2026 | B of A Securities | Initiates | Buy | $8.00 |
| 29 June 2026 | Evercore ISI Group | Maintains | Outperform | $5.00 → $6.00 |
| 29 June 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 26 June 2026 | Chardan Capital | Maintains | Buy | — |
| 26 June 2026 | Chardan Capital | Maintains | Buy | $4.00 → $3.00 |
| 26 June 2026 | Jones Trading | Maintains | Buy | — |
| 26 June 2026 | Jones Trading | Maintains | Buy | $11 → $10 |
| 9 Apr 2026 | Chardan Capital | Maintains | Buy | — |
| 4 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 8 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 27 June 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 27 June 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 13 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 29 Apr 2025 | Evercore ISI Group | Initiates | Outperform | — |
| 14 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 14 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Feb 2025 | Jones Trading | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PRQR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, ProQR Therapeutics NV returned −40.8% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 13% of US stocks
Cheaper than 40% of US stocks
Cheaper than 74% of US stocks
Higher than 93% of US stocks
Higher than 86% of US stocks
Higher than 14% of US stocks
Higher than 2% of US stocks
Higher than 20% of US stocks
Higher than 19% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ProQR Therapeutics NV has a market value of $193.3M and an enterprise value of $94.5M.
Revenue in the twelve months to 30 June 2026: $18.4M. The latest quarter grew 120.4% year on year.
Net income over the same four quarters: −$42.0M, a −228.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$50.2M.
Trailing P/E: −3.4×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
ProQR Therapeutics NV employs 186 people — $99K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ProQR Therapeutics NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ProQR announced upcoming presentations on clinical and preclinical progress with AX-0810 and AX-0811, as well as its Axiomer RNA editing platform, at four named conferences.
Why it matters — The presentations will provide PRQR watchers with updates on the company’s programs and platform.
ProQR Therapeutics announced first-in-human data for AX-0810, providing dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is advancing NTCP programs for cholestatic liver diseases, initially focusing on pediatric biliary atresia.
Why it matters — This marks the first human validation of ProQR's RNA-editing platform, a key step for its liver disease pipeline that PRQR watchers would be following closely.
ProQR Therapeutics N.V. (PRQR) held a shareholder/analyst call, the transcript of which has been published on Seeking Alpha. The excerpt provided only indicates that the call transcript is available, without detailing the content of the discussion.
Why it matters — A PRQR watcher would care because the transcript provides insight into management commentary and company updates from the official call.
ProQR announced the appointment of Chris Hart as Chief Data and AI Officer and the addition of Thomas Wolf to its Board of Directors as Strategic AI Advisor. These appointments support ProQR's strategy to scale AI across drug discovery and development using its Axiomer RNA editing platform and pipeline program AX-0811.
Why it matters — The appointments signal ProQR's expanded focus on AI-enabled drug discovery, which directly supports its ongoing development programs and upcoming clinical data readouts across four development programs.
ProQR Therapeutics announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. The company also announced a virtual investor and analyst educational event scheduled for September 30, 2026.
Why it matters — This marks the initiation of clinical development for AX-0811, an RNA-editing candidate based on ProQR's Axiomer platform, giving PRQR watchers an early read on the program's progress.
The 9 Wall Street analysts covering ProQR Therapeutics NV have a median 12-month price target of $8, with estimates ranging from $3 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering ProQR Therapeutics NV, 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ProQR Therapeutics NV 46 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, ProQR Therapeutics NV ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (70 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +467.4% from the last close, and Ticker Nerd's factor model ranks ProQR Therapeutics NV 46 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ProQR Therapeutics NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRQR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $10 over the next 12 months.
ProQR Therapeutics NV returned -40.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
ProQR Therapeutics N.V. Ordinary Shares represent ownership in ProQR Therapeutics N.V., a clinical-stage biotechnology company focused on RNA-based medicines.
The most recent item we track (GlobeNewsWire, 28 Oct 2026): "ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences". ProQR announced upcoming presentations on clinical and preclinical progress with AX-0810 and AX-0811, as well as its Axiomer RNA editing platform, at four named conferences.
ProQR Therapeutics N.V. Ordinary Shares represent ownership in ProQR Therapeutics N.V., a clinical-stage biotechnology company focused on RNA-based medicines. ProQR develops therapies built on its Axiomer RNA editing platform, which is designed to address genetic disorders with unmet medical needs. Its current work centers on discovering and developing novel therapeutic candidates for severe rare diseases, with particular attention to inherited conditions and other genetic targets. The company operates in the biotechnology and healthcare sectors, where RNA medicine is an important area of research because it aims to modify disease-related genetic messages rather than conventional protein targets. ProQR Therapeutics N.V. serves as a specialized participant in the broader life sciences market, supporting research, clinical development, and potential commercialization pathways for next-generation genetic therapies. Headquartered in Leiden, the Netherlands, the company also maintains a presence in Cambridge, Massachusetts.
CEO Mr. Daniel Anton de Boer · 186 employees · Netherlands · https://www.proqr.com
